Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…Abstract Number: 1594 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, Depression and Anti N-Methyl-D-Aspartate Receptor Antibodies and Anti- Ribosomal P In Systemic Lupus Erythematosus Patients In Argentina
Background/Purpose: Cognitive dysfunction (CD) and depression (D) are common manifestations of neuropsychiatric systemic lupus erythematosus (SLE) and they have been linked to antibodies (abs) like…Abstract Number: 725 • 2013 ACR/ARHP Annual Meeting
Localization At The Immunological Synapse Of Adaptor Protein Grb2 and PLC Gamma-1 In Non-Stimulated Peripheral Blood T Lymphocytes From Patients With Systemic Lupus Erythematosus Suggests An In Vivo dysregulated Activation State
Background/Purpose: We previously showed an increased metabolic rate of transmembrane adaptor protein LAT in TCR/CD3 stimulated lupus T cells, associated with delocalization of this adaptor…Abstract Number: 554 • 2013 ACR/ARHP Annual Meeting
Identification Of Stage Specific Genes Associated With Lupus Nephritis and Response To Remission induction In NZB/W Mice
Background/Purpose: Our goal was to use transcriptome analysis to elucidate the molecular mechanisms involved in the immunopathogenesis of renal inflammation during the onset, remission and…Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…Abstract Number: 1600 • 2013 ACR/ARHP Annual Meeting
Anti-Ribosomal P Protein Antibodies Exacerbate Long-Term Prognosis In Patients With Diffuse Neuropsychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematous
Background/Purpose: Systemic lupus erythematous (SLE) is a chronic inflammatory disease characterized by the expression of a variety of autoantibodies. Although the comprehensive survival from the…Abstract Number: 646 • 2013 ACR/ARHP Annual Meeting
Expression Of Interferon-Inducible Gene (Lymphocyte Antigen 6 Complex Locus E) In Systemic Lupus Erythematosus Patients and Its Association With Disease Activity
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation resulting in the production of antinuclear and other autoantibodies, generation of…Abstract Number: 540 • 2013 ACR/ARHP Annual Meeting
Exploration Of a Novel Therapeutic Target In a Murine Model Of Systemic Lupus Erythematosus: Targeting Sphingosine-1-Phosphate (S1P) Receptors
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by symptomatic flares that often result in terminal organ failure. The pathogenesis is characterized by…Abstract Number: 2891 • 2013 ACR/ARHP Annual Meeting
Loss Of Caspase 8 Exacerbates Dendritic Cell Activation In a MyD88- and RIPK1-Dependent Manner That Is Controlled By Inhibitory Molecules Transcribed By IRF3
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE). While DCs from SLE patients exhibit elevated activation,…Abstract Number: 1765 • 2013 ACR/ARHP Annual Meeting
Complement Component C5a Permits The Co-Existence Of Pathogenic Th17 Cells and Type I Interferon In Lupus
Background/Purpose: Systemic lupus erythematosus (SLE) is a type I interferon (IFN-I)-driven autoimmune disorder with exaggerated B and T-helper (Th) cell responses. Th17 cells, a recently…Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…Abstract Number: 630 • 2013 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Highly Increased On Circulating Microparticles In SLE Patients and Co-Localizes With IgG In Glomerular Deposits In Human Lupus Nephritis
Background/Purpose: The origin of autoantigens in glomerular immune complex (IC) deposits in lupus nephritis patients is unknown. They may derive from the circulation (microparticle (MP)-ICs…Abstract Number: 41 • 2013 ACR/ARHP Annual Meeting
Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity
Background/Purpose: Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex including CUL4A, DDB1, and ROC-1. CC-220 is a novel immunomodulatory compound currently in…Abstract Number: 2894 • 2013 ACR/ARHP Annual Meeting
Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus
Background/Purpose: In healthy individuals, TREM-1 proteins are cell surface receptors expressed by hematopoietic cells of the myeloid lineage. TREM-1 is a potent amplifier of proinflammatory…Abstract Number: 1699 • 2013 ACR/ARHP Annual Meeting
Development Of Systemic Lupus Erythamatosus Among “Possible Systemic Lupus Erythamatosus ” Patients Seen In Consultation: Long-Term Follow-Up
Background/Purpose: Rheumatology consultation to rule out SLE is common. However, in a substantial proportion of patients, SLE can be neither confirmed nor ruled out at…
ACR Meeting Abstracts